Type2 Diabetes Mellitus Clinical Trial
Official title:
Effects of Short-Message Notifications on Medication Adherence, Physical Activity and Fasting Blood Glucose Control and Correlation of These With the Health-Related Quality of Life in Mid-aged Diabetic Patients
NCT number | NCT04733612 |
Other study ID # | 20135 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | June 30, 2016 |
Est. completion date | February 26, 2018 |
Verified date | January 2021 |
Source | Istanbul University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The objective of our study was to assess awareness-raising of medication adherence (MA), physical activity (PA), fasting blood glucose (FBG), and glycated hemoglobin A (HbA1c) values by providing information on diabetes via short message (SMS) technology.
Status | Completed |
Enrollment | 125 |
Est. completion date | February 26, 2018 |
Est. primary completion date | December 20, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years to 64 Years |
Eligibility | Inclusion Criteria: - Clinical diagnosis of Type 2 Diabetes Mellitus (T2DM) between the last 1 and 10 years - Being aged between 40 and 64 years old, - Is treated for a minimum of 1 year with at least one oral antidiabetic drug. Exclusion Criteria: - Clinical diagnosis of T2DM for less than 1 year or more than 10 years. - Those who have had surgery or a cardiac event in the last 3 months or during the investigation. - Those under 40 and over 64 years of age. - Patients with T2DM that have not been treated with oral antidiabetic medication. - Volunteers who once did not participate in the control examinations in both groups were excluded from the evaluation. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Istanbul University |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Fasting blood glucose | After 8 hours of fasting in the morning, venous whole blood samples were taken to yellow capped tubes for fasting blood glucose (mmol/dL). | Beginning | |
Primary | Change from Baseline Fasting blood glucose at 3 months | After 8 hours of fasting in the morning, venous whole blood samples were taken to yellow capped tubes for fasting blood glucose (mmol/dL). | 3 months after beginning | |
Primary | Change from Baseline Fasting blood glucose at 6 months | After 8 hours of fasting in the morning, venous whole blood samples were taken to yellow capped tubes for fasting blood glucose (mmol/dL). | 6 months after beginning | |
Primary | Glycated hemoglobin A (HbA1c) | In the HbA1c evaluation (%), after 8 hours of fasting by volunteers, venous whole blood samples were taken in purple tubes (EDTA) between 08:00 and 10:00 a.m. and evaluated by the HPLC method. | Beginning | |
Primary | Change from Baseline of Glycated hemoglobin A (HbA1c) at 3 months | In the HbA1c evaluation (%), after 8 hours of fasting by volunteers, venous whole blood samples were taken in purple tubes (EDTA) between 08:00 and 10:00 a.m. and evaluated by the HPLC method | 3 months after beginning | |
Primary | Change from Baseline of Glycated hemoglobin A (HbA1c) at 6 months | In the HbA1c evaluation (%), after 8 hours of fasting by volunteers, venous whole blood samples were taken in purple tubes (EDTA) between 08:00 and 10:00 a.m. and evaluated by the HPLC method | 6 months after beginning | |
Primary | Physical Activity level | The International Physical Activity Questionnaire (IPAQ) was used to evaluate the physical activity level of the participants at the beginning of the study.
This measure assesses the types of intensity of physical activity and sitting time that people do as part of their daily lives are considered to estimate total physical activity in MET-min/week and time spent sitting. The higher scores mean a better outcome. |
Beginning | |
Primary | Change from Baseline Physical Activity at 3 months | The International Physical Activity Questionnaire (IPAQ) was used to evaluate the physical activity level of the participants at at 3 months after the beginning of the study.
This measure assesses the types of intensity of physical activity and sitting time that people do as part of their daily lives are considered to estimate total physical activity in MET-min/week and time spent sitting. The higher scores mean a better outcome. |
3 months from beginning | |
Primary | Change from Baseline Physical Activity at 6 months | The International Physical Activity Questionnaire (IPAQ) was used to evaluate the change in physical activity level of the participants at at 6 months after the beginning of the study.
This measure assesses the types of intensity of physical activity and sitting time that people do as part of their daily lives are considered to estimate total physical activity in MET-min/week and time spent sitting. The higher scores mean a better outcome. |
6 months from beginning | |
Primary | Drug Adherence | The Morisky Medication Adherence Scale (MMAS-8) was used to assess the compliance of patients with drug treatment.
If the patient scores higher on the scale, they will be assessed as more adherent. If they score lower on the scale, they are presumed to be struggling with non-adherence. |
Beginning | |
Primary | Change from Baseline Drug Adherence at 3 months | The Morisky Medication Adherence Scale was used to assess the compliance of patients with drug treatment.
If the patient scores higher on the scale, they will be assessed as more adherent. If they score lower on the scale, they are presumed to be struggling with non-adherence. |
3 months after beginning | |
Primary | Change from Baseline Drug Adherence at 6 months | The Morisky Medication Adherence Scale (MMAS-8) was used to assess the compliance of patients with drug treatment.
If the patient scores higher on the scale, they will be assessed as more adherent. If they score lower on the scale, they are presumed to be struggling with non-adherence. |
6 months after beginning | |
Primary | Quality of Life Assessed by SF-36v2 | The Short-Form Health Survey (SF-36v2) is used to asses the quality of life of volunteers'. It has 36 items grouped in 8 dimensions: physical functioning, physical and emotional limitations, social functioning, bodily pain, general and mental health. The higher scores mean a better outcome. | Beginning | |
Primary | Change from Baseline Quality of Life Assessed by SF-36v2 at 3 months | The Short-Form Health Survey (SF-36v2) is used to asses the quality of life of volunteers'. It has 36 items grouped in 8 dimensions: physical functioning, physical and emotional limitations, social functioning, bodily pain, general and mental health. The higher scores mean a better outcome. | 3 months after beginning | |
Primary | Change from Baseline Quality of Life Assessed by SF-36v2 at 6 months | The Short-Form Health Survey (SF-36v2) is used to asses the quality of life of volunteers'. It has 36 items grouped in 8 dimensions: physical functioning, physical and emotional limitations, social functioning, bodily pain, general and mental health. The higher scores mean a better outcome. | 6 months after beginning | |
Secondary | Baseline blood pressure | The volunteers' systolic and diastolic blood pressure (mmHg) was measured by a physician through a manual cuff and stethoscope after sitting for at least 5 minutes, from the left arm at the level of the heart, as suggested in the literature. | Beginning | |
Secondary | Change from Baseline blood pressure at 3 months | The volunteers' systolic and diastolic blood pressure (mmHg) was measured by a physician through a manual cuff and stethoscope after sitting for at least 5 minutes, from the left arm at the level of the heart, as suggested in the literature. | 3 months after beginning | |
Secondary | Change from Baseline blood pressure at 6 months | The volunteers' systolic and diastolic blood pressure (mmHg) was measured by a physician through a manual cuff and stethoscope after sitting for at least 5 minutes, from the left arm at the level of the heart, as suggested in the literature. | 6 months after beginning | |
Secondary | Baseline heart rate | The volunteers' heart rate count was measured by a finger-type pulse oximeter, from the index finger of the right or left hand after resting for at least 5 minutes. | Beginning | |
Secondary | Change from Baseline heart rate at 3 months | The volunteers' heart rate count was measured by a finger-type pulse oximeter, from the index finger of the right or left hand after resting for at least 5 minutes. | 3 Months After Beginning | |
Secondary | Change from Baseline heart rate at 6 months | The volunteers' heart rate count was measured by a finger-type pulse oximeter, from the index finger of the right or left hand after resting for at least 5 minutes. | 6 Months After Beginning | |
Secondary | Baseline Body Mass Index | The height (cm) of the volunteers was obtained in the morning, after 8 hours of fasting, without shoes, standing upright, by measuring the distance from the top of the head to the floor with a calibrated stadiometer. Body weight (kg) were measured in the morning after 8 hours of fasting, with light clothing and bare feet, with a calibrated and valid 'Tanita Body Composition Analyzer TBF-410GS' brand bioelectrical impedance analyzer.
Body Mass Index (BMI) is calculated using a person's height and weight as shown in formula: BMI = kg/m2 where kg is a person's weight in kilograms and m2 is their height in meter square. |
Beginning | |
Secondary | Change from Baseline Body Mass Index at 3 months | The height (cm) of the volunteers was obtained in the morning, after 8 hours of fasting, without shoes, standing upright, by measuring the distance from the top of the head to the floor with a calibrated stadiometer. Body weight (kg) were measured in the morning after 8 hours of fasting, with light clothing and bare feet, with a calibrated and valid 'Tanita Body Composition Analyzer TBF-410GS' brand bioelectrical impedance analyzer.
Body Mass Index (BMI) is calculated using a person's height and weight as shown in formula: BMI = kg/m2 where kg is a person's weight in kilograms and m2 is their height in meter square. |
3 months after Beginning | |
Secondary | Change from Baseline Body Mass Index at 6 months | The height (cm) of the volunteers was obtained in the morning, after 8 hours of fasting, without shoes, standing upright, by measuring the distance from the top of the head to the floor with a calibrated stadiometer. Body weight (kg) were measured in the morning after 8 hours of fasting, with light clothing and bare feet, with a calibrated and valid 'Tanita Body Composition Analyzer TBF-410GS' brand bioelectrical impedance analyzer.
Body Mass Index (BMI) is calculated using a person's height and weight as shown in formula: BMI = kg/m2 where kg is a person's weight in kilograms and m2 is their height in meter square. |
6 months after Beginning | |
Secondary | Baseline body fat ratios | The body fat ratios were measured in the morning after 8 hours of fasting, with light clothing and bare feet, with a calibrated and valid 'Tanita Body Composition Analyzer TBF-410GS' brand bioelectrical impedance analyzer. | Beginning | |
Secondary | Change from Baseline Body Fat Ratios at 3 Months | The body fat ratios were measured in the morning after 8 hours of fasting, with light clothing and bare feet, with a calibrated and valid 'Tanita Body Composition Analyzer TBF-410GS' brand bioelectrical impedance analyzer. | 3 Months After Beginning | |
Secondary | Change from Baseline Body Fat Ratios at 6 Months | The body fat ratios were measured in the morning after 8 hours of fasting, with light clothing and bare feet, with a calibrated and valid 'Tanita Body Composition Analyzer TBF-410GS' brand bioelectrical impedance analyzer. | 6 Months After Beginning | |
Secondary | Baseline waist/hip ratio | The volunteers waist and hip circumference and waist/hip ratio were measured by tape measure after 8 hours of fasting in the morning with thin clothes on them.
Waist circumference (cm) was measured at the level of the umbilicus and hip circumference (cm) at the level of the femur trochanter major. Waist/hip ratio (WHR) were were calculated as follows waist/hip ratio= waist circumference / hip circumference |
Beginning | |
Secondary | Change from Baseline waist/hip ratio at 3 Months | The volunteers waist and hip circumference and waist/hip ratio were measured by tape measure after 8 hours of fasting in the morning with thin clothes on them.
Waist circumference (cm) was measured at the level of the umbilicus and hip circumference (cm) at the level of the femur trochanter major. Waist/hip ratio (WHR) were were calculated as follows waist/hip ratio= waist circumference / hip circumference |
3 Months after Beginning | |
Secondary | Baseline Diet and Nutritional Habits | The last three days' food intake form is used to collect the information about daily nutritional habits of volunteers'. The amount of food and the frequency are marked. | Beginning | |
Secondary | Change from Baseline Diet and Nutritional Habits at 3 months | The last three days' food intake form is used to collect the information about daily nutritional habits of volunteers'. The amount of food and the frequency are marked. | 3 Months after Beginning | |
Secondary | Change from Baseline Diet and Nutritional Habits at 6 months | The last three days' food intake form is used to collect the information about daily nutritional habits of volunteers'. The amount of food and the frequency are marked. | 6 Months after Beginning | |
Secondary | Baseline Energy Intake | From the last three days' food intake form the average calories (kcal) of macro and micronutrients are calculated. | Beginning | |
Secondary | Change from Baseline Energy Intake at 3 months | From the last three days' food intake form the average calories (kcal) of macro and micronutrients are calculated. | 3 months after Beginning | |
Secondary | Change from Baseline Energy Intake at 6 months | From the last three days' food intake form the average calories (kcal) of macro and micronutrients are calculated. | 6 months after Beginning |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04082091 -
Screening, Early Referral and Lifestyle Tailored E_prescription for Cardiovascular Prevention
|
||
Active, not recruiting |
NCT02248311 -
"Preventing Cardiovascular Ischemic Events and Arresting Their Consequences in Type 2 Diabetic Population
|
N/A | |
Completed |
NCT02653300 -
A Pilot Study to Assess the Safety of Oral Insulin in Patients With Nonalcolholic Steatohepatitis (NASH)
|
Phase 2 | |
Completed |
NCT03655535 -
Multicenter Study to Evaluate the Effect of BTI320 on Glycemic Control in Type 2 Diabetes
|
Phase 2 | |
Completed |
NCT03256747 -
Effects of Neuromuscular Electrical Stimulation on Glucose Variability in Patients With Type 2 Diabetes
|
N/A | |
Completed |
NCT05343767 -
Investigate the Efficacy and Safety of Low-Glu in Patients Newly Diagnosed With Type II Diabetes Mellitus
|
N/A | |
Withdrawn |
NCT03675074 -
Neujia Anastomosis for Treatment of Obesity and Type II Diabetes
|
N/A | |
Withdrawn |
NCT03190798 -
Effects of Canagliflozin on Intravascular Volume and Hemodynamics
|
Phase 4 | |
Withdrawn |
NCT03437330 -
Empagliflozin Effect on Glucose Toxicity
|
Phase 4 | |
Withdrawn |
NCT03008395 -
Empowerment, Motivation and Medical Adherence (EMMA).
|
N/A | |
Not yet recruiting |
NCT05539066 -
AI Health Assistant and Type 2 Diabetes
|
N/A | |
Completed |
NCT03682445 -
Metabolic, Physical Responses To Exercise In Patients With Type 2 Diabetes Mellitus
|
N/A | |
Not yet recruiting |
NCT03239119 -
The Effectivity and Safety Study of rExenatide-4 in Chinese Type 2 Diabetes Mellitus
|
Phase 3 | |
Completed |
NCT03259789 -
Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
|
Phase 3 | |
Recruiting |
NCT03506230 -
Financial Incentives for Low Socioeconomic Diabetic Patients
|
N/A | |
Completed |
NCT03072407 -
MAD Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PB-119 to Subjects With T2DM
|
Phase 1 | |
Completed |
NCT05668442 -
Feasibility of an Online Exercise Community Among Individuals With Type 2 Diabetes
|
||
Completed |
NCT02964572 -
Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 Diabetes
|
N/A | |
Completed |
NCT02956044 -
Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin
|
Phase 1 | |
Completed |
NCT02628392 -
A Phase 2 Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)
|
N/A |